The authors investigated relationships between the protective efficacy of neoantigen hydrophobicity and low/intermediate and high tumor mutational burdens (TMB) in people with melanoma (n = 151) treated with programmed cell death protein-1 (PD-1)/PD-L1-targeted immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.